New FDA-Cleared Assay to Aid in Diagnosis of Inflammatory Bowel Disease
By LabMedica International staff writers Posted on 30 Jun 2014 |
A new quantitative ELISA for calprotectin helps diagnosis inflammatory bowel disease as well as differentiates it from irritable bowel syndrome.
INOVA Diagnostics Inc. (San Diego, CA, USA) has launched QUANTA Lite Calprotectin, an important new FDA-cleared in vitro diagnostic (IVD) assay that aids in the diagnosis of Inflammatory Bowel Disease (IBD) and which can also help differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical findings.
The accurate detection of calprotectin levels in stool can provide critical information to physicians in determining appropriate care for patients suffering from gastrointestinal disorders. QUANTA Lite Calprotectin is a 96-well, quantitative enzyme linked immunosorbent assay (ELISA) that detects calprotectin concentration in human feces.
This assay further expands the INOVA Diagnostics portfolio in the area of autoimmune gastrointestinal disorders. "We are very pleased to launch this high-performing assay to meet the increasing demand from laboratories worldwide," said Michael Mahler, PhD, Vice President of Research and Development for INOVA Diagnostics, "Inaccurate diagnosis at the screening level can contribute to unnecessary procedures and increased healthcare costs. The QUANTA Lite Calprotectin assay can improve patient care while potentially reducing overall costs." Roger Inglès, CEO of INOVA Diagnostics, added, "The benefits of fecal calprotectin testing are being recognized by healthcare systems around the world, as evidenced by the recent recommendation from the National Institute for Health and Care Excellence (NICE) in the UK. As a worldwide leader in the autoimmunity IVD market, INOVA Diagnostics is perfectly positioned to quickly increase awareness and adoption of this important new test."
Related Links:
INOVA Diagnostics
INOVA Diagnostics Inc. (San Diego, CA, USA) has launched QUANTA Lite Calprotectin, an important new FDA-cleared in vitro diagnostic (IVD) assay that aids in the diagnosis of Inflammatory Bowel Disease (IBD) and which can also help differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical findings.
The accurate detection of calprotectin levels in stool can provide critical information to physicians in determining appropriate care for patients suffering from gastrointestinal disorders. QUANTA Lite Calprotectin is a 96-well, quantitative enzyme linked immunosorbent assay (ELISA) that detects calprotectin concentration in human feces.
This assay further expands the INOVA Diagnostics portfolio in the area of autoimmune gastrointestinal disorders. "We are very pleased to launch this high-performing assay to meet the increasing demand from laboratories worldwide," said Michael Mahler, PhD, Vice President of Research and Development for INOVA Diagnostics, "Inaccurate diagnosis at the screening level can contribute to unnecessary procedures and increased healthcare costs. The QUANTA Lite Calprotectin assay can improve patient care while potentially reducing overall costs." Roger Inglès, CEO of INOVA Diagnostics, added, "The benefits of fecal calprotectin testing are being recognized by healthcare systems around the world, as evidenced by the recent recommendation from the National Institute for Health and Care Excellence (NICE) in the UK. As a worldwide leader in the autoimmunity IVD market, INOVA Diagnostics is perfectly positioned to quickly increase awareness and adoption of this important new test."
Related Links:
INOVA Diagnostics
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form